全文获取类型
收费全文 | 116762篇 |
免费 | 31470篇 |
国内免费 | 1100篇 |
专业分类
耳鼻咽喉 | 2537篇 |
儿科学 | 3304篇 |
妇产科学 | 2792篇 |
基础医学 | 5269篇 |
口腔科学 | 5211篇 |
临床医学 | 29091篇 |
内科学 | 27763篇 |
皮肤病学 | 3673篇 |
神经病学 | 14213篇 |
特种医学 | 3907篇 |
外科学 | 19758篇 |
综合类 | 309篇 |
现状与发展 | 40篇 |
一般理论 | 41篇 |
预防医学 | 16156篇 |
眼科学 | 2441篇 |
药学 | 2402篇 |
中国医学 | 25篇 |
肿瘤学 | 10400篇 |
出版年
2024年 | 559篇 |
2023年 | 5160篇 |
2022年 | 1322篇 |
2021年 | 3355篇 |
2020年 | 5749篇 |
2019年 | 2615篇 |
2018年 | 7555篇 |
2017年 | 7800篇 |
2016年 | 8417篇 |
2015年 | 8499篇 |
2014年 | 11168篇 |
2013年 | 13239篇 |
2012年 | 5547篇 |
2011年 | 5378篇 |
2010年 | 7740篇 |
2009年 | 9879篇 |
2008年 | 4898篇 |
2007年 | 3939篇 |
2006年 | 4942篇 |
2005年 | 3388篇 |
2004年 | 2665篇 |
2003年 | 2183篇 |
2002年 | 2095篇 |
2001年 | 1904篇 |
2000年 | 1209篇 |
1999年 | 1774篇 |
1998年 | 2241篇 |
1997年 | 2040篇 |
1996年 | 2053篇 |
1995年 | 1767篇 |
1994年 | 1170篇 |
1993年 | 989篇 |
1992年 | 776篇 |
1991年 | 657篇 |
1990年 | 527篇 |
1989年 | 536篇 |
1988年 | 501篇 |
1987年 | 387篇 |
1986年 | 366篇 |
1985年 | 306篇 |
1984年 | 274篇 |
1983年 | 311篇 |
1982年 | 246篇 |
1981年 | 214篇 |
1980年 | 128篇 |
1978年 | 126篇 |
1977年 | 124篇 |
1976年 | 96篇 |
1974年 | 80篇 |
1972年 | 74篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献2.
3.
4.
5.
6.
7.
8.
9.
Melanie A. Krook Julie W. Reeser Gabrielle Ernst Hannah Barker Max Wilberding Gary Li Hui-Zi Chen Sameek Roychowdhury 《British journal of cancer》2021,124(5):880
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer 相似文献